Genentech Bails on Altus
522221
Altus Pharmaceuticals still testing drug after Genentech leaves development partnership.
444613
Shares of pharmaceutical companies OSI  Pharmaceuticals Inc. OSIP.O and Genentech Inc. DNA.N fell  sharply before the bell on Friday on concerns about the price  and a warning label on a key new drug the two collaborated to  produce.
194383
Biotechnology company Genentech Inc  said on Monday its fourth-quarter profit rose 6.4 percent, but sales of several drugs, including blockbuster cancer drug Avastin, fell short of investor expectations, sending the company's shares lower.
176562
By Karen Attwood  The Dutch healthcare and chemicals group Akzo Nobel ditched plans to float its biopharmaceutical division in favour of a sale yesterday, triggering speculation it would next make a move on the chemicals group Imperial Chemical Industries.
372947
Stocks of branded and generic drug makers closed down a bit Tuesday as clinical study results mixed with merger updates. One of the big winners on the day was Nektar Therapeutics, on news that Exubera, the
257114
Genentech Inc. (DNA.N: Quote, Profile, Research) on Wednesday said third-quarter earnings rose 50 percent, spurred by growth in new colon cancer treatment Avastin and strong sales of its
68730
Today, Seesmic, the company founded by Loic Lemeur, announced their initial $6 million funding. Several people noticed that my name isn't on the list of investors.  I'll probably end up kicking myself when Seesmic becomes the next Google or YouTube. I remain a fan of the company and Loic and his team and will be rooting for them.  Why did I get cold feet? It has nothing to do with the product or the company, both of which appear to be outstanding. It's the stock market. I had to make the final Seesmic decision as I was getting out of stock, at a significant loss. The only stock I hold now is AAPL, and sadly, it's way under the price I paid for it a few months ago. Like a lot of other investors, right now stocks give me the willies. I will likely get back in, slowly, a little bit every week to average out the price, hoping the market has found a bottom.
725490
Genelabs Technologies Inc. GNLB.O  said on Tuesday that a late-stage trial of its drug to limit  bone loss in women with lupus disease failed to work, sending  the company's shares down 75 percent.
82032
To turn its new multiple sclerosis treatment Antegren into a blockbuster drug with more than $1 billion in annual sales, Biogen Idec and its partner, Elan Pharmaceuticals, might not have to persuade doctors that it is superior to existing interferon treatments. Partial data released by the companies appear to confirm the treatment's outstanding clinical performance.
625668
Biotechnology company Clinical Data Inc. said it is selling its Dutch diagnostics business to France's ELITech Group for $15 million to focus on its core business. Newton-based Clinical Data said it will hold about $4.5 million in cash from Vital Scientific BV, netting $19.5 million on the transaction. Clinical Data said the $4.5 million was from cash on the company's ...
307489
Genzyme Corp. chief executive Henri A. Termeer's conference call with Wall Street on May 8, 2003, quickly turned ugly. Analysts peppered him with questions about the Cambridge biotech company's plan to buy back shares of its biosurgery division. The price, they said, was far too low.
530503
Meanwhile, back in the data centre... Symantec announced today it would cough up $830m for infrastructure management software firm Altiris.â¦
632359
Shares of Atherogenics Inc. opened down 7.2 percent on the Nasdaq Wednesday following a pre-market report that the drug developer is abandoning further clinical trials of its AGIX-4207 treatment for rheumatoid arthritis.
481843
Security software vendor Symantec announced Monday it has agreed to acquire Altiris, a maker of asset management software, in a cash deal valued at about $830 million. Altiris counts Dell, IBM and Microsoft as partners who sell its products to businesses.
421575
Genentech and OSI Pharmaceuticals won federal approval yesterday to sell Tarceva, a pill to treat lung cancer. The approval by the Food and Drug Administration came well before the agency&#39;s
365281
Genentech Inc.  said on  Tuesday second-quarter profit rose 79 percent on demand for  cancer medicines and raised its full-year forecast, but its  stock fell as sales of colon cancer drug Avastin disappointed.
44693
Celera Genomics Group of Rockville announced an agreement Tuesday to provide potential targets for cancer drugs to biotech giant Genentech Inc. -The Washington Post